LumosVar — a name inspired by Harry Potter — could help physicians provide genomic-based treatments for their patients
By conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program developed by the Translational Genomics Research Institute (TGen), “light up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.
A study published today in the scientific journal Frontiers in Oncology describes how researchers at TGen, an affiliate of City of Hope, developed LumosVar to create a tool that can accurately identify cancer-causing mutations from patient tumor samples.
In the case of archived samples from patients for which treatment outcome results are known, these represent a treasure trove of information that could accelerate research by investigators and physicians in predicting responses of future patients to particular treatments.
“There are many open questions in precision oncology that can only be answered by collecting large amounts of patient genomic data linked to treatment response and clinical outcomes,” said Dr. Rebecca Halperin, a Research Assistant Professor in TGen’s Quantitative Medicine and Systems Biology Program.
“The approach we outline in this study should enable researchers to use archival samples more effectively. Accurately calling, or identifying, somatic variants — those DNA changes specific to a patient’s cancer — are the first step in any analysis,” said Dr. Halperin, the study’s lead author.
However, archived tumor samples are frequently not accompanied by the patients’ normal — or germline — genetic information, making it difficult to distinguish the patient’s normal DNA variants to their mutated and cancerous DNA changes.
LumosVar is a precise enough tool that it not only can detect the cancerous DNA from a patient sample, but it also can differentiate the adjacent normal DNA that may surround the tumor in the sample. Comparing the patient’s normal DNA from a suspected cancer-causing mutation is critical to eliminating benign, non-cancerous variants in the sample — “false positives” — and ensuring that the tissue sample analysis is as accurate as possible.
A high level of accuracy is needed for physicians to use this information in precision medicine, determining what treatment each individual patient should receive.
“The sequencing of DNA from tissue adjacent to the tumor could help identify somatic, or cancer-causing, mutations when another source of normal tissue is not available,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Integrated Cancer Genomics Division, and also the study’s senior author.
The Latest on: Genomic-based treatments
via Google News
The Latest on: Genomic-based treatments
- Answering the call for real-time plant disease diagnostics in resource-poor regionson August 13, 2019 at 2:13 am
Just like with human disease, if you see visible symptoms but aren’t sure of the causal agent, then how can you action the correct treatment ... Implementing portable genomic-based diagnostics for ...
- These 3 ETFs Have Crushed It in 2019on April 2, 2019 at 4:19 am
Elsewhere, companies that are merging healthcare and technology in the pursuit of genomic-based treatments have shown a lot of promise lately. Advances in areas like stem-cell research, targeted ...
- As if by magic: Program lights up cancer-causing mutationson March 20, 2019 at 1:46 pm
(2019, March 20). As if by magic: Program lights up cancer-causing mutations: LumosVar -- a name inspired by Harry Potter -- could help physicians provide genomic-based treatments for their patients.
- Implementing Precision Medicine in Community-Based Oncology Programs: Three Modelson February 24, 2019 at 4:00 pm
The use of precision medicine and the number of genomic-based treatments and immunotherapies is increasing. Nevertheless, oncology providers face challenges to implementing precision medicine, ...
- Grail to initiate largest ever UK cancer screening studyon December 4, 2018 at 4:46 am
That initiative builds on the 100,000 Genome Project, and data from that could soon be integrated into medical records, a move which could help the UK's NHS become a world leader in introducing ...
- Financial constraints dampen adoption of personalised treatment for breast cancer in India: Oncologistson August 4, 2018 at 1:00 am
Financial constraints prevent 95 per cent Indian women with early breast cancer from opting for genomic based personalized treatment, said Mumbai based oncologists. Personalized medicine guided by ...
- Westport pharma startup tables IPOon August 25, 2017 at 8:13 am
Accelerated Pharma canceled its plans for an initial public offering of stock, with the firm listing its headquarters in Westport and developing genomic-based treatments for cancer. Founded in 2014 ...
- Genomic-based Diagnostic Approach may Help Treat Cardiovascular Diseaseson August 23, 2017 at 5:27 pm
Due to rapid pace of genomic discovery, gaps in genetic literacy and paucity of big Indian trials, the genomic-based diagnostic and treatment approach is at best, overwhelming to the current ...
- In oncology the patients are afraid of the treatment more than the disease: Dr. Somashekhar S.Pon May 4, 2016 at 8:25 pm
The unfortunate scenario in oncology is that most of the time patients are afraid of the treatment more than the disease. They thought that the ... very advanced immunotherapies, genomic based ...
- Broad genetic testing for childhood cancer patients can pinpoint cancer causes and identify potential treatmentson January 27, 2016 at 3:59 pm
In the same issue of JAMA Oncology, a team led by investigators from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported similarly successful efforts to generate genomic-based ...
via Bing News